NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status.

Author(s): Hatse S, Brouwers B, Dalmasso B, Laenen A, Kenis C, Schöffski P, Wildiers H

Publication: PLoS One, 2014, Vol. 9, Page e110644

PubMed ID: 25333486 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to determine the effect of patient age and condition on serum or plasma levels of microRNA (miR, miRNA).

Conclusion of Paper

None of the 15 miR initially found to be differentially expressed between the serum of older and younger breast cancer patients were found to be differentially expressed in the plasma of a different cohort of older and younger breast cancer patients or between the plasma of fit and frail older breast cancer patients.

Studies

  1. Study Purpose

    The purpose of this study was to determine the effect of patient age and condition on serum or plasma levels of miR. Levels of 175 miRNA were compared in serum specimens from 10 young (28-38 years, mean 34.5 years) breast cancer patients and 10 older (80-89 years, mean 82.8 years) breast cancer patients by real-time qRT-PCR panels. Levels of 15 select miRNA were validated by real-time qRT-PCR using plasma from 10 young breast cancer patients (37-43 year, mean 40.6 years), 10 older "fit" (Leuven Oncology Frailty Score, LOFS= 10) breast cancer patients (71-83 years, mean 78.1 years) and 10 older frail (LOFS ≤6) breast cancer patients (73-91 years, mean 78.4 years). Serum and plasma specimens were frozen at -80°C.

    Summary of Findings:

    An initial study found levels of miR-320b, miR-210, miR-21, miR -378, and miR-423-5p to be higher and miR-301a, miR-376a, miR-374a, miR-20a-3p, let-7d, miR-191, miR-200c, miR-30b-5p, miR-140b-5p, and miR-106b-5p to be lower in the serum of older versus younger breast cancer patients (p<0.01, all). Further, let-7i, miR-29a, miR-29c, miR-140-3p, and miR-484 were identified to be stably expressed and were not affected by patient age, but let-7i was excluded as a normalizer based on the literature. Significantly lower levels of miR-20a-3p, miR-301a, miR-374a, miR-30b-5p, miR-106b-5p and miR-191 and higher levels of miR-378 in plasma from older patients than younger patients were confirmed in a second cohort, but after correction for multiple testing, none of these differences were significant.

                         

    Biospecimens
    Preservative Types
    • Frozen
    Diagnoses:
    • Neoplastic - Carcinoma
    Platform:
    AnalyteTechnology Platform
    RNA Low density array
    RNA Real-time qRT-PCR
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Preaquisition Patient age Mean 34.5 years
    Mean 82.8 years
    Mean 40.6 years
    Mean 78.1 years
    Mean 78.4 years
    Preaquisition Diagnosis/ patient condition Fit
    Frail
    Biospecimen Aliquots and Components Blood and blood products Plasma
    Serum
    Real-time qRT-PCR Specific Targeted nucleic acid miR-320b
    miR-210
    miR-21
    miR-378
    miR-423-5p
    miR-301a
    miR-376a
    miR-374a
    miR-20a-3p
    let-7d
    miR-191
    miR-200c
    miR-30b-5p
    miR-140b-5p
    miR-106b-5p
    let-7i
    miR-29a
    miR-29c
    miR-140-3p
    miR-484

You Recently Viewed  

comments powered by Disqus

News and Announcements

  • Most Popular SOPs in 2018

  • New Article Published from NCI's Biospecimen Pre-analytical Variables (BPV) Program

  • 2019 Annual ISBER Meeting

  • More...